CSL Limited (ASX:CSL) has announced the successful completion of its $6.3 billion institutional placement with proceeds to support the company's acquisition of Vifor Pharma.
CSL completes $6.3 billion placement to support Vifor acquisition
December 16, 2021 Latest NewsBioPharma
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News


